Selected article for: "article scope and upstream target"
Author: Jasenosky, Luke D.; Cadena, Cristhian; Mire, Chad E.; Borisevich, Viktoriya; Haridas, Viraga; Ranjbar, Shahin; Nambu, Aya; Bavari, Sina; Soloveva, Veronica; Sadukhan, Supriya; Cassell, Gail H.; Geisbert, Thomas W.; Hur, Sun; Goldfeld, Anne E.
Title: The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
  • Document date: 2019_8_8
    • ID: yomg30hg_32
    Snippet: Although NTZ is FDA approved for the treatment of cryptosporidial diarrhea and is a well-tolerated medication, a limitation of the data presented here regarding NTZ's inhibition of EBOV is that it is based on in vitro studies and we have not yet established NTZ's efficacy against EBOV in an in vivo animal model. Furthermore, the detailed investigation of NTZ's upstream target in the regulation of the immune responses described here is outside the.....
    Document: Although NTZ is FDA approved for the treatment of cryptosporidial diarrhea and is a well-tolerated medication, a limitation of the data presented here regarding NTZ's inhibition of EBOV is that it is based on in vitro studies and we have not yet established NTZ's efficacy against EBOV in an in vivo animal model. Furthermore, the detailed investigation of NTZ's upstream target in the regulation of the immune responses described here is outside the scope of this article and will be the subject of future studies, as will in vivo testing of NTZ against EBOV.

    Search related documents:
    Co phrase search for related documents
    • EBOV inhibition and NTZ EBOV inhibition: 1, 2, 3, 4
    • future study and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • future study and vitro study: 1, 2, 3, 4
    • future study and vivo testing: 1
    • immune response and NTZ EBOV inhibition: 1
    • immune response and upstream target: 1
    • immune response and vitro study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • immune response and vivo animal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • immune response and vivo animal model: 1, 2
    • immune response and vivo testing: 1
    • NTZ EBOV efficacy and vivo animal: 1
    • vitro study and vivo animal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • vitro study and vivo testing: 1, 2, 3, 4, 5, 6